Introduction {#s001}
============

T[ype]{.smallcaps} 2 [diabetes]{.smallcaps} (T2D) is a progressive disease, in which an ongoing decline in β-cell function is associated with glycemic deterioration over time.^[@B1]^ Treatment guidelines generally recommend a sequential approach to treatment of T2D, with stepwise escalation of treatment if the glycated hemoglobin (HbA1c) target is not met after ∼3 months.^[@B2]^ Due to the need for lifetime pharmacotherapy, patients may remain on therapies for long periods of time without data to inform their likely course. Thus, long-term data on the efficacy and safety of glucose-lowering therapies are important. However, long-term clinical studies are not often conducted due to the challenges of retaining patients in a trial over time and the considerable effort required from patients, coordinators, and investigators to continue the study.

A microsphere-based extended-release formulation of the glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide, which is administered subcutaneously once weekly (QW), was initially studied in the Diabetes Therapy Utilization: Researching Changes in A1C, Weight, and Other Factors Through Intervention With Exenatide Once Weekly (DURATION-1) trial. This study, conducted in patients with T2D treated with lifestyle modification or oral glucose-lowering therapies (metformin, sulfonylurea, thiazolidinedione, or any two of these agents), comprised a 30-week controlled period followed by an open-ended, open-label extension. All patients in the extension study (*N* = 258; 87.5% of the intent-to-treat \[ITT\] population) were treated with exenatide QW, either continuing from the controlled period or switching from exenatide twice daily (BID) to exenatide QW. Results from the 6-month and 1-, 2-, 3-, and 5-year assessments of HbA1c, fasting plasma glucose (FPG), body weight, and adverse events have previously been reported.^[@B3]^ The purpose of this analysis was to examine the safety, efficacy, and changes in glucose-lowering therapy, and to assess key subpopulations, among patients with T2D treated with exenatide QW, continuously for up to 6 years in the DURATION-1 trial.

Materials and Methods {#s002}
=====================

Study design {#s003}
------------

The study design of DURATION-1 has been reported previously.^[@B3]^ Briefly, the original study enrolled patients aged ≥16 years with T2D (HbA1c of 7.1%--11.0%) treated for ≥2 months before screening with diet modification and exercise, or pharmacotherapy with metformin, sulfonylurea, thiazolidinedione, or a combination of any two of these agents. Exenatide BID and QW was administered by subcutaneous injection. Patients received exenatide BID 5 μg for 3 days before randomization, then were randomized to receive exenatide QW 2 mg, or exenatide BID (5 μg for the first 4 weeks and then 10 μg) through week 30. At 30 weeks, patients entered an uncontrolled, open-label, open-ended study phase in which all patients received exenatide QW 2 mg. The study was initially conducted with a precommercial grade of exenatide QW, but patients transitioned to commercial-grade exenatide QW during the extension period. Patients were not followed up after discontinuation from the study, but measurements from the final visit were available.

Restrictions on concomitant medication use were eased over time. Medication changes were allowed if deemed necessary by the investigator or primary care physician but had to be reported to the study sponsor. Added glucose-lowering medications were identified by Anatomical Therapeutic Chemical codes, and the addition of drugs (not neutral change between brand and generic forms) was verified by an AstraZeneca physician. Data for changes in dose or substitution of medications within a class were not available.

A common clinical protocol was approved for each study site by the appropriate institutional review board. Patients provided written informed consent before study participation. The study was conducted in accordance with the principles described in the Declaration of Helsinki, including all amendments through to the South Africa revision of 1996.^[@B8]^

Endpoints {#s004}
---------

During the open-ended extension period, patients visited the clinic weekly during weeks 31--34, 2 weeks later at week 36, at 4-week intervals during weeks 40--76, and subsequently at 8-week intervals until study end or the early termination visit. Endpoints assessed for each visit during the open-ended extension period included vital signs, height, and weight; HbA1c, FPG (in mg/dL; divide by 18 for mmol/L), and homeostatic model assessment (HOMA) of β-cell function (HOMA-B) and insulin sensitivity (HOMA-S); adverse events (including injection-site examination) that were coded according to the Medical Dictionary for Regulatory Activities (version 17.0); and medication review. During the open-ended extension period, assessments at each visit from week 36 onward included anthropometric measures, fasting insulin, proinsulin, glucagon, lipids, anti-exenatide antibodies, chemistry, hematology, and urinalysis. Data are presented for the visits at specific weeks that correspond approximately with years 1--6.

Statistical analysis {#s005}
--------------------

Efficacy analyses utilized the 6-year completer population, which comprised patients who completed 6 years (312 weeks) of treatment, whether they remained active in the study or withdrew after 6 years. The last observation carried forward approach was applied to estimate missing postbaseline values by treatment. For patients who were assigned to receive exenatide BID during the controlled period, available data after week 30 were used to impute subsequent missing data for exenatide QW. Safety analyses utilized the ITT population, comprising individuals who received ≥1 dose of exenatide.

The primary analysis method for changes in HbA1c was analysis of variance (ANOVA; general linear model, including the original treatment assignment, baseline HbA1c stratum, and concomitant sulfonylurea use at screening), as prespecified in the statistical analysis plans for the 30- and 52-week data analyses. To account for individual patient\'s baseline HbA1c, a secondary analysis was performed using analysis of covariance (ANCOVA; general linear model, including the original treatment assignment, concomitant sulfonylurea use at screening, and baseline HbA1c values). Secondary parameters were analyzed using ANCOVA (general linear model including the original treatment assignment, baseline HbA1c stratum, concomitant sulfonylurea use at screening, and baseline values for the respective parameters). Least-squares means (LSM), standard errors, and 95% confidence intervals (CIs) were calculated for changes from baseline in efficacy parameters. For adverse events, overall incidences within the ITT population were calculated. Exposure-adjusted incidence among ITT patients receiving exenatide QW during the controlled and extension periods was also calculated.

Post-hoc analyses were conducted to study the timing of specific events over the study duration. Such analyses assessed the addition of non-GLP-1RA glucose-lowering medications and the timing of key adverse events, including nausea, injection-site reactions, hypoglycemia with and without sulfonylureas and insulin, and serious adverse events.

Post-hoc analyses also examined patient subpopulations of interest. These key patient subpopulations included patients with no changes or additions to concomitant glucose-lowering medications over 6 years; patients who discontinued before completing 6 years of treatment (noncompleters); and patients with systolic blood pressure (BP) \>130 mmHg at baseline (for BP changes). Where calculation of inferential statistics was appropriate, the ANCOVA model described above was used.

Results {#s006}
=======

The ITT population comprised 295 patients ([Fig. 1A](#f1){ref-type="fig"}); of these, 258 patients (87.5%) continued in the extension period and 136 (46%) completed at least 6 years of treatment and were included in the 6-year completer population ([Fig. 1B](#f1){ref-type="fig"}). Demographics and baseline characteristics in the ITT and 6-year completer and noncompleter populations are shown in [Table 1](#T1){ref-type="table"}. Compared to noncompleters, completers were slightly older (*P* = 0.016), had a lower baseline HbA1c (*P* = 0.014), and were more often white (*P* = 0.034) ([Table 1](#T1){ref-type="table"}). All other baseline characteristics were comparable between completers and noncompleters.

###### 

**(A)** Patient disposition. **(B)** Kaplan--Meier plot of time to withdrawal and estimates of proportion of patients remaining in study. **(C)** Kaplan--Meier plot of time to addition of new glucose-lowering medication. **(D)** Time course of use of the most common concomitant glucose-lowering therapies in 6-year completers (*n* = 136). Point estimates and 95% confidence intervals for Kaplan--Meier plots were calculated for the time the first event was observed in each year. BID, twice daily; ITT, intent-to-treat; LCL, lower confidence limit; QW, once weekly; UCL, upper confidence limit.
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###### 

[Demographics and Baseline Characteristics]{.smallcaps}

                                                          *ITT population (*N = *295)*   *6-Year completers (*n = *136)*   *6-Year noncompleters (*n = *159)*
  ------------------------------------------------------- ------------------------------ --------------------------------- ------------------------------------
  Male                                                    157 (53.2)                     73 (53.7)                         84 (52.8)
  Age at consent,^[a](#tf2){ref-type="table-fn"}^ years   55.0 ± 9.7                     56.5 ± 8.5                        53.8 ± 10.5
  Race/ethnicity^[b](#tf3){ref-type="table-fn"}^                                                                           
   White^[c](#tf4){ref-type="table-fn"}^                  230 (78.0)                     114 (83.8)                        116 (73.0)
   Black                                                  28 (9.5)                       15 (11.0)                         13 (8.2)
   Hispanic                                               36 (12.2)                      6 (4.4)                           30 (18.9)
   Asian                                                  1 (0.3)                        1 (0.7)                           0 (0.0)
  Duration of T2D, years                                  6.7 ± 5.0                      7.1 ± 5.7                         6.4 ± 4.3
  HbA1c,^[a](#tf2){ref-type="table-fn"}^ %                8.30 ± 0.99                    8.14 ± 0.93                       8.43 ± 1.03
  FPG, mg/dL                                              169.4 ± 42.9                   165.7 ± 41.0                      172.6 ± 44.3
  Body weight, kg                                         101.8 ± 19.9                   101.1 ± 17.5                      102.5 ± 21.8
  T2D management method at screening                                                                                       
   SU-based                                               109 (36.9)                     53 (39.0)                         56 (35.2)
    SU only                                               16 (5.4)                       9 (6.6)                           7 (4.4)
    SU+metformin                                          82 (27.8)                      38 (27.9)                         44 (27.7)
    SU+TZD                                                10 (3.4)                       5 (3.7)                           5 (3.1)
    SU+metformin+TZD                                      1 (0.3)                        1 (0.7)                           0 (0.0)
   Non-SU based                                           186 (63.1)                     83 (61.0)                         103 (64.8)
    Diet and exercise                                     43 (14.6)                      17 (12.5)                         26 (16.4)
    Metformin only                                        106 (35.9)                     48 (35.3)                         58 (36.5)
    TZD only                                              9 (3.1)                        7 (5.1)                           2 (1.3)
    Metformin+TZD                                         28 (9.5)                       11 (8.1)                          17 (10.7)

Data are *n* (%) or mean ± standard deviation.

*P* \< 0.05 for completers versus noncompleters.

Percentages may not total 100% due to rounding.

*P* \< 0.05 for the proportion of white patients for completers versus noncompleters.

FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; ITT, intent-to-treat; SU, sulfonylurea; T2D, type 2 diabetes; TZD, thiazolidinedione.

Of the 136 completers, 78 (57%) added no new glucose-lowering medications during the 6-year follow-up period ([Fig. 1C](#f1){ref-type="fig"}). At screening and at endpoint, metformin and sulfonylureas were the most commonly used concomitant glucose-lowering therapies. Use of metformin and sulfonylureas appeared to increase during the trial, whereas use of thiazolidinediones appeared to decrease ([Fig. 1D](#f1){ref-type="fig"}). Addition of insulin was observed after 12 months of treatment. Insulin use was less frequent than use of oral therapies (fast-acting, up to 2.9%; intermediate-acting, 0.7%; long-acting, 8.8%). Few patients received dipeptidyl peptidase-4 inhibitors (up to 2.9%) or bromocriptine (0.7%) and none used sodium-glucose cotransporter-2 inhibitors.

Glycemic measures {#s007}
-----------------

Significant improvements in HbA1c from baseline were observed in the 6-year completer population at each annual time point, including at 6 years, as assessed by ANOVA (LSM change, −1.6% \[95% CI, −1.8, −1.4\]; [Fig. 2A](#f2){ref-type="fig"}), the primary outcome measure. Significant HbA1c improvements from baseline were also seen by ANCOVA (LSM change, −1.1% \[95% CI, −1.2, −0.9\]; [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}; Supplementary Data are available at [www.liebertonline.com/dia](www.liebertonline.com/dia)). At years 1, 2, 3, 4, 5, and 6, HbA1c \<7.0% was achieved by 79.4%, 63.2%, 60.3%, 59.6%, 46.3%, and 46.3% of 6-year completers, respectively, and HbA1c ≤6.5% was achieved by 63.2%, 43.4%, 35.3%, 39.7%, 31.6%, and 33.1%, respectively. At each annual time point, including 6 years, 6-year completers had significant improvements from baseline in FPG (LSM change, −28 mg/dL \[95% CI, −37, −18\]; [Fig. 2B](#f2){ref-type="fig"}). The 6-year completer population also demonstrated improvements from baseline over time in β-cell function and insulin sensitivity as measured by HOMA (HOMA-B and HOMA-S, respectively). The HOMA-B score was increased from baseline by 78% at year 1 and subsequently declined but remained elevated relative to baseline (21% at year 6; [Supplementary Table S1](#SD2){ref-type="supplementary-material"}). The HOMA-S score was increased from baseline at each annual time point (by 28% at year 6; [Supplementary Table S1](#SD2){ref-type="supplementary-material"}).

###### 

Key efficacy parameters in all 6-year completers (*n* = 136) and those not on additional glucose-lowering medications (*n* = 78). LSM ± SE changes from baseline in **(A)** HbA1c by ANOVA, **(B)** FPG, and **(C)** body weight. \**P* \< 0.05 for change from baseline. ANOVA, analysis of variance; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; LSM, least-squares mean; SE, standard error.
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Cardiovascular risk factors {#s008}
---------------------------

Body weight significantly improved from baseline at each annual time point and after 6 years (LSM change, −4.2 kg \[95% CI, −5.8, −2.6\]; [Fig. 2C](#f2){ref-type="fig"}). At 6 years, significant improvements in multiple measures of dyslipidemia from baseline were also observed ([Supplementary Table S1](#SD2){ref-type="supplementary-material"}), including total cholesterol (LSM change, −10.1 mg/dL \[95% CI, −17.0, −3.1\]), low-density lipoprotein (LDL) cholesterol (LSM change, −9.8 mg/dL \[95% CI, −15.6, −4.0\]), high-density lipoprotein (HDL) cholesterol (LSM change, +2.6 mg/dL \[95% CI, 0.7, 4.5\]), LDL/HDL cholesterol ratio (median change, −0.2 \[range, −2.1, +3.4\]), and triglycerides (median change, −8.0 mg/dL \[range, −307, +431\]). Reductions from baseline in systolic and diastolic BP were observed in the completer population but were not maintained throughout the study ([Supplementary Table S1](#SD2){ref-type="supplementary-material"}). The subgroup of patients with baseline systolic BP ≥130 mmHg had reductions from baseline in systolic and diastolic BP that were significant at most annual time points through to 6 years (LSM \[95% CI\], −9.9 \[−15.4, −4.4\]/−5.8 \[−9.1, −2.4\] mmHg).

Patients with no additional glucose-lowering medications {#s009}
--------------------------------------------------------

Six-year completers who received no additional glucose-lowering medications had significant reductions from baseline in HbA1c at each annual time point, including at 6 years, as assessed by ANOVA (LSM change, −1.8% \[95% CI, −2.1, −1.6\]; [Fig. 2A](#f2){ref-type="fig"}) and ANCOVA (LSM change, −1.3% \[95% CI, −1.5, −1.1\]; [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). At 6 years, HbA1c goals of \<7.0% and ≤6.5% were achieved by 55.1% and 41.0% of patients, respectively. Similarly, this subgroup had significant reductions from baseline in FPG at each annual time point through to 6 years (LSM change, −26.0 mg/dL \[95% CI, −35.0, −16.9\]; [Fig. 2B](#f2){ref-type="fig"}). Reductions in body weight observed in this subgroup were numerically greater than in the overall cohort (LSM change at 6 years, −6.1 kg \[95% CI, −7.5, −4.6\]) and more stable over time ([Fig. 2C](#f2){ref-type="fig"}).

Improvements in levels of total cholesterol (LSM change, −13.2 mg/dL \[95% CI, −20.9, −5.5\]), LDL cholesterol (LSM change, −10.9 mg/dL \[95% CI, −17.7, −4.0\]), HDL cholesterol (LSM change, 2.7 mg/dL \[95% CI, 0.6, 4.7\]), and triglycerides (median change, −17.0 mg/dL \[range, −307, +149\]) were also observed at 6 years among 6-year completers who received no additional glucose-lowering medications; however, reductions in systolic and diastolic BP were nonsignificant, with LSM changes of −0.2 mmHg (95% CI, −3.4, 2.9) and −1.4 mmHg (95% CI, −3.3, 0.5), respectively.

Of the 78 completers who received no additional glucose-lowering medications, 24 (30.8%) reported nausea during treatment with exenatide QW during the 6 years of follow-up.

Patients who discontinued therapy {#s010}
---------------------------------

The mean time to discontinuation of study treatment in 6-year noncompleters was 903 days (2.5 years). Six-year noncompleters were observed to respond to therapy, with a mean (±standard deviation) change in HbA1c of −0.7% ± 1.4%, FPG of −14 ± 58 mg/dL, and body weight of −2.7 ± 6.3 kg at study endpoint (i.e., each patient\'s last measurement in the study). Of the 159 noncompleters, 64 (40.3%) reported nausea adverse events during the initial 30-week assessment period and 36 (22.6%) reported nausea during the open-ended assessment period.

Safety and tolerability {#s011}
-----------------------

In this subgroup of 136 patients choosing to continue on therapy, no incremental or unexpected safety findings were observed with long-term exenatide QW treatment. Treatment-emergent adverse events with an incidence of ≥10% over the open-ended extension period are shown in [Table 2](#T2){ref-type="table"}. Nausea (mostly mild) was the most common adverse event with exenatide QW during the initial controlled period. Subsequently, the incidence of nausea decreased (from 0.846 to 0.076 events/year), as did the incidence of injection-site pruritus (from 0.510 to 0.016 events/year) and injection-site erythema (from 0.137 to 0.013 events/year).

###### 

[Treatment-Emergent Adverse Events with an Incidence of ≥10% Reported in Patients Receiving Exenatide Once Weekly During the 30-Week or Open-Ended Assessments Through 6 Years (Intent-to-treat Population)]{.smallcaps}

                                      *30-Week assessment (*n = *148)*   *Open-ended assessment (*n = *278)*          
  ----------------------------------- ---------------------------------- ------------------------------------- ------ -------
  Upper respiratory tract infection   8.1                                0.162                                 41.9   0.172
  Nasopharyngitis                     6.8                                0.187                                 28.3   0.160
  Diarrhea                            16.2                               0.373                                 26.0   0.102
  Sinusitis                           4.7                                0.087                                 21.7   0.104
  Arthralgia                          4.7                                0.124                                 19.0   0.067
  Back pain                           4.7                                0.087                                 18.6   0.057
  Urinary tract infection             10.1                               0.224                                 18.2   0.076
  Nausea                              27.0                               0.846                                 17.1   0.076
  Pain in extremity                   0.7                                0.025                                 15.9   0.050
  Vomiting                            10.8                               0.361                                 15.5   0.069
  Hypertension                        3.4                                0.062                                 15.1   0.043
  Bronchitis                          2.7                                0.050                                 14.3   0.047
  Musculoskeletal pain                1.4                                0.025                                 13.6   0.042
  Cough                               3.4                                0.062                                 10.5   0.032
  Gastroenteritis, viral              8.1                                0.149                                 10.1   0.033
  Constipation                        10.1                               0.199                                 9.7    0.028
  Injection-site pruritus             18.2                               0.510                                 5.4    0.016

Serious adverse events were reported in 58 ITT patients (22.5%) during the extension period (ranging from 4.0% to 8.7% in the 6-month intervals during the open-ended assessment period; [Supplementary Table S2](#SD3){ref-type="supplementary-material"}). Treatment-emergent adverse events leading to withdrawal were infrequent (6.2%) during the extension period. The adverse events leading to withdrawal in \>1 patient were nausea (*n* = 2) and T2D progression (loss of glucose control; *n* = 2).

Adverse events of special interest were rare during the 6 years of follow-up: one case of pancreatitis (annual rate of 0.001 events/year; considered related to treatment and led to withdrawal), one case of pancreatic carcinoma (not considered related to treatment and led to withdrawal), and two cases of acute renal failure (not considered related to treatment and did not lead to withdrawal) were reported.

No major hypoglycemia events were reported. Most minor hypoglycemia events over 6 years occurred with concomitant sulfonylurea use; 28.6% of patients with sulfonylurea use at screening and 6.4% with no sulfonylurea use reported ≥1 minor hypoglycemia event. The time course of nausea showed a decreased incidence after the initial controlled period, while the incidence of hypoglycemia initially decreased but subsequently increased ([Supplementary Fig. S2](#SD4){ref-type="supplementary-material"}).

Small mean (± standard deviation) increases from baseline in the heart rate were seen throughout the 6-year observation period (2.1 \[9.6\] beats/min at 6 years), but the magnitude of the change did not increase over time ([Supplementary Table S1](#SD2){ref-type="supplementary-material"}).

Discussion {#s012}
==========

Long-term data on the efficacy and tolerability of treatment for T2D provide important information for both physicians and patients. Results of this analysis show that, over 6 years of treatment, patients treated with exenatide QW who remained on therapy demonstrated sustained improvements from baseline in clinical parameters relating to glycemic control, measures of β-cell function and insulin sensitivity, and cardiovascular risk factors. In addition, a considerable proportion of these patients consistently achieved HbA1c goals, satisfying therapeutic guidelines. These data also showed no new pattern or increased incidence of adverse events over time on therapy.

To date, few glucose-lowering therapies have demonstrated efficacy and safety out to 6 years, although 2- and 3-year analyses have been conducted for several GLP-1RAs, including exenatide BID and QW. In the Liraglutide Effect and Action in Diabetes (LEAD)-3 trial, in which 43% of patients completed 2 years of treatment, the mean changes from baseline in HbA1c were −0.9% and −1.1% for liraglutide 1.2 and 1.8 mg, respectively.^[@B9]^ In the HARMONY 3 study, 68% of patients completed 2 years of treatment with albiglutide (including 26% of completers who received hyperglycemic rescue therapy), leading to a mean change from baseline in HbA1c of −0.63%.^[@B10]^ In a long-term extension study of exenatide BID, the mean change from baseline in HbA1c was −1.0% in patients completing 3 years of treatment (41%).^[@B11]^ In the 63% of patients who completed 3 years of treatment with exenatide QW in the DURATION-3 study, the mean change from baseline in HbA1c was −1.1%.^[@B12]^ The mean change in HbA1c was also −1.1% in a pooled analysis of patients treated with exenatide QW for 2.5--3 years in the DURATION-1, −2, and −3 trials.^[@B13]^ Thus, these findings contribute to the small number of studies demonstrating long-term efficacy with GLP-1RA treatment.

The investigator and patient investment in such a long-term study should not be underestimated, with over 50 study visits and measurements of HbA1c and other parameters per patient during the 6 years of follow-up. Accordingly, only 46% of the initial ITT population completed 6 years of treatment. This context must be considered for proper interpretation of the results. For example, although HbA1c \<7.0% was achieved by 63 (46.3%) 6-year completers, this amounts to 21.4% of the overall ITT population. Furthermore, it is not surprising that some patients would have had additions to their glucose-lowering therapy regimens over this long study duration, although over half of the 6-year completers did not receive any additional glucose-lowering therapies during the study, and changes in glycemic parameters in patients without such additions were similar to those in completers overall.

Given the progressive nature of T2D, it would be expected to see indications of disease progression during a study of this duration. Initial mean improvements in HOMA-B were attenuated over the course of the study, although improvement was still observed with exenatide QW at 6 years. Similarly, increases were observed following the initial mean reduction in FPG, suggesting gradual loss of glycemic control. Although the patients remaining on treatment for 6 years still had progressive T2D, most managed their hyperglycemia without insulin.

Since the completer population is a self-selected population of patients who continued therapy, it may be suggested that its results are influenced by withdrawal of patients who experienced inadequate glucose control or adverse events. Analysis of the last data available for patients who discontinued shows that mean reductions in HbA1c and FPG were lower in noncompleters than in 6-year completers, and 10 patients had documented withdrawal due to loss of glucose control over the 6 years. Similarly, the incidence of nausea in noncompleters during the initial 30-week assessment (40%) was higher than that in completers (24%). Overall, 33 patients withdrew due to adverse events during the course of the study, most often due to nausea. However, given the nature and duration of this extension trial, it is equally possible that patients discontinued for personal reasons such as lack of time or interest, relocation, or trial fatigue, consistent with the "withdrawal of consent" designation that was the most common reason for discontinuation.

Significant mean body weight reductions of ≥1.5 kg were observed from years 1--6, although the degree of weight loss was diminished in the middle years of assessment. This may be attributable, at least in part, to changes to concomitant glucose-lowering medication regimens in some patients, although changes in patient compliance with dietary advice were not recorded. The mean weight loss observed in the 6-year completers who had no additions to their glucose-lowering regimen during the course of follow-up was greater and more stable than in the overall cohort of completers.

Previous short-term studies suggest that common adverse events primarily occur early in therapy with GLP-1RAs.^[@B14],[@B15]^ No incremental safety findings were observed with up to 6 years of exenatide QW treatment in the current study of a self-selected population. The exposure-adjusted event rates of nausea and injection-site reactions with exenatide QW were lower during the extension period than during the 30-week controlled period. The incidence of hypoglycemia remained consistently low over the course of the study. A small increase in heart rate (approximately 2--3 beats/min) was also noted. Although this has been observed for multiple GLP-1RAs, the mechanism for this effect is unclear.^[@B16]^

The nature of this follow-up analysis is associated with limitations. There was no control group in the extension phase, and the open-label study design has the potential to affect expectations and perceptions of treatment and to create bias. Also, the efficacy analysis was conducted on the completer population, a nonrandomized subset of the ITT population. Although this approach may represent a subset of patients who responded well to treatment during the initial controlled study period or were more adherent, it was deemed to be the most informative analysis for the nature and duration of this long-term study. Although the subgroup of patients with no additions to glucose-lowering therapies had greater and more stable weight loss, we were unable to explore the influence of discontinuing concomitant therapies; in particular, some weight loss may have occurred in patients who discontinued thiazolidinediones or sulfonylureas. Changes in practice may have affected the trial; due to new clinical perspectives regarding cardiovascular profiles of T2D treatments, routine use of thiazolidinediones decreased during the course of the trial,^[@B17]^ potentially contributing, at least partially, to the gradual mean weight loss after year 3. Data were not collected on patient dieting or other lifestyle changes that could have influenced body weight findings.

Further information on the long-term efficacy of exenatide QW will be explored in the ongoing Exenatide Study of Cardiovascular Event Lowering (EXSCEL) Trial ([ClinicalTrials.gov](ClinicalTrials.gov) identifier: NCT01144338), which will compare the effects of usual care with or without exenatide QW on major cardiovascular outcomes in ∼14,000 patients with T2D over an anticipated duration of up to 7.5 years.

Conclusions {#s013}
===========

In this long-term extension study, treatment with exenatide QW in 46% of patients who chose to remain in the trial over 6 years was associated with clinically significant, sustained improvements in glycemic control and weight without unexpected safety findings. These data support the efficacy and safety of long-term therapy with exenatide QW.
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